TEMPERATURE-RELEASE CATALYST FOR CROSS-LINKING HALYURONIC ACID DURING INJECTION
Systems and methods for cosmetic augmentation by forming a biocompatible cross-linked polymer having a multi-phase mixture with a temperature activated catalyst; injecting the mixture into a patient as a homogeneous fluid; activating the catalyst to cross-link the polymer at a predetermined temperature in a patient; and augmenting soft tissue with the biocompatible cross-linked polymer.
1 . A method for cosmetic augmentation, comprising:
forming a biocompatible cross-linked polymer having a multi-phase mixture with a temperature activated catalyst;
injecting the mixture into a patient as a homogeneous fluid;
activating the catalyst to cross-link the polymer at a predetermined temperature in a patient; and
augmenting soft tissue with the biocompatible cross-linked polymer.
2 . The method of claim 1 , comprising providing a predetermined controlled release of selected pharmaceutical substance to modulate soft tissue response to the polymer.
3 . The method of claim 1 , comprising cross-linking the polymer in a shell inside the patient.
4 . The method of claim 1 , wherein the polymer comprises one of:
collagens, hyaluronic acids, celluloses, proteins, saccharides.
5 . The method of claim 1 , wherein the polymer comprises an extracellular matrix of a biological system.
6 . The method of claim 1 , comprising using cross linkers and forming homo-polymers or to form copolymers by crosslinking with other polymer species.
7 . The method of claim 1 , comprising adding a substance to the composition for biocompatibility.
8 . The method of claim 1 , comprising controlling drug releases at predetermined timing in anticipation of an onset of a negative physiological event in response to invading foreign bodies.
9 . The method of claim 1 , comprising fast releasing the composition.
10 . The method of claim 1 , comprising adding anesthetics, lidocaine or compound to reduce or eliminate acute inflammatory reactions to the pharmaceutical substance.
11 . The method of claim 1 , comprising adding one or more compositions selected from the group consisting of steroids, corticosteroids, dexamethasone, triamcinolone.
12 . The method of claim 1 , comprising providing a slow release substance to the pharmaceutical substance.
13 . The method of claim 1 , comprising providing an antiproliferative compound.
14 . The method of claim 1 , wherein the substance comprises paclitaxel, serolimas.
15 . The method of claim 1 , comprising controlling the scar formation process around a foreign body including capsular formation.
16 . The method of claim 1 , comprising providing a medium release to the pharmaceutical substance.
17 . The method of claim 1 , comprising optimizing degradation profile of the composition.
18 . The method of claim 1 , comprising minimizing migration of the composition.
19 . The method of claim 1 , comprising controlling an average molecular weight (Mn) and the polydispersity index.
20 . The method of claim 1 , comprising characterizing a target tissue, and maintaining a consistency of the composition in particle size and population densities.
21 . The method of claim 1 , comprising co-cross-linking glycosaminoglycan chemically with at least one other polymer including hyaluronan or hylan.
22 . The method of claim 1 , comprising adding a biodegradable surfactant or plasticizer to reduce surface tension of material as it is injected into a patient through a small diameter needle.
23 . The method of claim 1 , comprising storing the catalyst as microspheres and melting the microspheres at body temperature to release the catalyst.
24 . The method of claim 1 , comprising modeling a 3D model of a human body and continuously updating a current shape of breast or butt from the 3D model to fit to a desired shape.
25 . The method of claim 1 , comprising injecting with a mechanical pump the biocompatible crosslinked polymer under soft tissue in a minimally invasive manner.
26 . A method for cosmetic augmentation, comprising:
forming a biocompatible cross-linked polymer having a multi-phase mixture with a predetermined controlled release of selected pharmaceutical substance to modulate soft tissue response to the polymer;
injecting the mixture into a patient and releasing a catalyst at a predetermined body temperature to cross-link the polymer in the patient;
filling a semi-permeable shell with the pharmaceutical substance; and
augmenting soft tissue with the biocompatible cross-linked polymer.